Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In

Why It Matters

The dispute highlights governance risk for a biotech still seeking commercial traction, while the outcome could affect Novavax’s ability to secure partnership milestones and restore investor confidence.

Key Takeaways

• Shah Capital, 9% shareholder, urges vote against Novavax board and pay
• Novavax’s 2024 Sanofi partnership generated only $22 million in sales
• Analyst sees catalyst in Sanofi’s pending Phase 3 data for combo vaccine
• Board reduction to five members proposed to improve governance and cost control
• Stock could rise to $18 target if R&D leadership cuts costs

Pulse Analysis

Novavax’s trajectory since its pandemic peak illustrates the challenges of transitioning from a crisis‑driven business to a sustainable biotech model. After soaring to roughly $290 per share in 2021, the company’s stock now trades below $10, reflecting waning demand for its protein‑based COVID‑19 vaccine and a series of costly operational missteps. While peers such as Moderna and BioNTech have diversified into oncology and other high‑margin pipelines, Novavax remains heavily reliant on a single product line and partnership agreements, leaving it vulnerable to market sentiment and activist scrutiny.

Activist hedge fund Shah Capital has reignited its campaign, leveraging its 9% stake to demand a board overhaul and reject the current executive compensation package. The firm’s letter cites the meager $22 million revenue from the 2024 Sanofi licensing deal and a pessimistic 2026 outlook as evidence of chronic underperformance. Shah also proposes shrinking the board from eight to five members, arguing that a leaner, more entrepreneurial slate could accelerate cost cuts and strategic focus. These demands come at a time when Novavax’s institutional credibility is low, with many investors maintaining short positions despite ongoing collaborations with Pfizer and Sanofi.

Wall Street analyst Mayank Mamtani offers a tempered view, acknowledging the validity of Shah’s concerns while emphasizing upcoming catalysts that could shift the narrative. A pending Phase 3 study for Sanofi’s COVID‑19‑influenza combination vaccine could unlock a $125 million milestone payment for Novavax, providing much‑needed cash flow. Additionally, the recent consolidation of R&D leadership under Dr. Robert Walker is expected to streamline expenses and improve execution. Mamtani retains a "buy" rating with an $18 price target, suggesting that if the partnership milestones materialize and governance reforms take hold, Novavax could recover a portion of its lost market value.